Clinical Trials Logo

Clinical Trial Summary

During this prospective observational study, the investigators collect the information about the outcomes of fecal microbiota transplantation in patients with blood disorders, performed to eradicate gut colonization with multidrug-resistant (MDR) bacteria.

Patients with blood disorders are characterized by poor diversity of gut microbiome, affected by repeated chemotherapy and antimicrobial treatments. This makes them vulnerable to colonization by pathogenic bacteria carrying genes responsible for antibiotic resistance. In case of gut mucosa injury and severe immune suppression, these colonizing bacteria may cause severe systemic infections. As the bacteria are secreted with the stool, the colonized patients become an epidemiologic threat to the others.

Fecal microbiota transplantation (FMT) was shown to be very efficient in treatment of relapsed and refractory Clostridium difficile infection and became a standard treatment. In home institution, the investigators use FMT not only in case of Clostridium difficile colitis, but also in case of gut colonization with multidrug-resistant (MDR) bacteria. This is based on assumption that physiological gut flora may outcompete the pathogenic bacteria similarly as in case of Clostridium difficile and lead to loss of colonization. The procedure is performed in all patients colonized, who qualify according to listed inclusion and exclusion criteria .


Clinical Trial Description

n/a


Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02461199
Study type Observational
Source Medical University of Warsaw
Contact Jaroslaw Bilinski, MD
Phone +48 22 599 29 44
Email jaroslaw.bilinski@gmail.com
Status Recruiting
Phase N/A
Start date February 2015
Completion date September 2017

See also
  Status Clinical Trial Phase
Terminated NCT02218151 - Medical Home Care for Hematopoietic Stem Cell Transplantation Phase 2 N/A
Completed NCT02095951 - Preemptive Ethanol Lock Therapy in Pediatric Bloodstream Infection Phase 4